GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Dyadic International Inc (NAS:DYAI) » Definitions » Shiller PE Ratio

Dyadic International (Dyadic International) Shiller PE Ratio : (As of Apr. 29, 2024)


View and export this data going back to 2004. Start your Free Trial

What is Dyadic International Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Dyadic International Shiller PE Ratio Historical Data

The historical data trend for Dyadic International's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Dyadic International Shiller PE Ratio Chart

Dyadic International Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - 459.23 157.56 78.98 -

Dyadic International Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 78.98 125.86 139.35 - -

Competitive Comparison of Dyadic International's Shiller PE Ratio

For the Biotechnology subindustry, Dyadic International's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Dyadic International's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Dyadic International's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Dyadic International's Shiller PE Ratio falls into.



Dyadic International Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Dyadic International's E10 for the quarter that ended in Dec. 2023 is calculated as:

For example, Dyadic International's adjusted earnings per share data for the three months ended in Dec. 2023 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=-0.08/129.4194*129.4194
=-0.080

Current CPI (Dec. 2023) = 129.4194.

Dyadic International Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201312 -0.014 98.326 -0.018
201403 -0.050 99.695 -0.065
201409 -0.030 100.428 -0.039
201412 -0.050 99.070 -0.065
201503 -0.010 99.621 -0.013
201506 -0.010 100.684 -0.013
201509 0.060 100.392 0.077
201512 1.880 99.792 2.438
201603 -0.020 100.470 -0.026
201606 0.010 101.688 0.013
201609 -0.030 101.861 -0.038
201612 -0.060 101.863 -0.076
201703 0.070 102.862 0.088
201706 -0.050 103.349 -0.063
201709 -0.050 104.136 -0.062
201712 -0.040 104.011 -0.050
201803 -0.070 105.290 -0.086
201806 -0.060 106.317 -0.073
201809 -0.060 106.507 -0.073
201812 -0.020 105.998 -0.024
201903 -0.080 107.251 -0.097
201906 -0.100 108.070 -0.120
201909 -0.060 108.329 -0.072
201912 -0.070 108.420 -0.084
202003 -0.080 108.902 -0.095
202006 -0.100 108.767 -0.119
202009 -0.090 109.815 -0.106
202012 -0.070 109.897 -0.082
202103 -0.120 111.754 -0.139
202106 -0.140 114.631 -0.158
202109 -0.060 115.734 -0.067
202112 -0.150 117.630 -0.165
202203 -0.090 121.301 -0.096
202206 -0.120 125.017 -0.124
202209 -0.060 125.227 -0.062
202212 -0.070 125.222 -0.072
202303 -0.030 127.348 -0.030
202306 -0.070 128.729 -0.070
202309 -0.060 129.860 -0.060
202312 -0.080 129.419 -0.080

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Dyadic International  (NAS:DYAI) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Dyadic International Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Dyadic International's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Dyadic International (Dyadic International) Business Description

Traded in Other Exchanges
N/A
Address
140 Intracoastal Pointe Drive, Suite 404, Jupiter, FL, USA, 33477
Dyadic International Inc is a global biotechnology platform company. The company has developed a gene expression platform for producing commercial quantities of industrial enzymes and other proteins, and has licensed this technology to third parties, such as Abengoa Bioenergy, BASF, Codexis and others, for use in industrial (non-pharmaceutical) applications. This technology is based on the Thermothelomyces heterothallica fungus, which the company named C1.
Executives
Ronen Tchelet officer: VP of Research and Bus. Dvlpmt 140 INTRACOASTAL POINTE DRIVE, SUITE 404, JUPITER X1 33477
Mark A Emalfarb director, 10 percent owner, officer: President, CEO & Chairman C/O DYADIC INTERNATIONAL, INC., 140 INTRACOASTAL POINT DRIVE, SUITE 404, JUPITER FL 33477-5094
Joseph P Hazelton officer: Chief Business Officer 140 INTRACOASTAL POINTE DRIVE, SUITE 404, JUPITER FL 33477
Francisco Trust Under Agreement Dated February 28, 1996 10 percent owner C/O ROBERT S. LEVIN, ESQ., TRUSTEE, 180 NORTH LASALLE STREET, SUITE 3200, CHICAGO IL 60601
Patrick K. Lucy director C/O PFENEX INC., 10790 ROSELLE STREET, SAN DIEGO CA 92121
Matthew S. Jones officer: Managing Dir of BD & Licensing 140 INTRACOASTAL POINTE DRIVE, SUITE 404, JUPITER X1 33477
Seth Herbst director 140 INTRACOASTAL POINTE DRIVE, SUITE 404, JUPITER X1 33477
Barry Buckland director C/O DYADIC INTERNATIONAL, INC., 140 INTERCOASTAL POINTE DR SUITE 404, JUPITER FL 33477
Ping Wang Rawson officer: Chief Financial Officer 140 INTRACOASTAL POINTE DRIVE, SUITE 404, JUPITER X1 33477
Michael P. Tarnok director KERYX BIOPHARMACEUTICALS, INC., 750 LEXINGTON AVENUE, NEW YORK NY 10022
Arindam Bose director 4452 BELTWAY DRIVE, ADDISON TX 75001
Jack Kaye director C/O KERYX BIOPHARMACEUTICALS, 750 LEXINGTON AVENUE, NEW YORK X1 10022
Tom Juda 10 percent owner 410 S LUCERNE BLVD, LOS ANGELES CA 90020
John Steven Emerson 10 percent owner 1522 ENSLEY AVENUE, LOS ANGELES CA 90024
Nancy Juda 10 percent owner 410 S LUCERNE BLVD, LOS ANGELES CA 90020